Related Experiment Video
Updated: May 3, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
19.4K
Prostate cancer biomarkers: an update
Javier Romero Otero1, Borja Garcia Gomez1, Felix Campos Juanatey2
1Hospital Universitario 12 Octubre, Madrid, Spain.
Urologic Oncology
|February 6, 2014
Summary
New prostate cancer biomarkers show promise beyond prostate-specific antigen (PSA), improving diagnosis and treatment selection. While validation is ongoing, markers like PCA 3 and proPSA offer advancements over traditional PSA testing.
Area of Science:
- Urology
- Oncology
- Biomarker Discovery
Background:
- Prostate-specific antigen (PSA) is the sole routine biomarker for prostate cancer but has limitations in distinguishing cancer from benign conditions and assessing aggressiveness.
- PSA's inability to accurately predict treatment response contributes to overtreatment and unnecessary biopsies.
Purpose of the Study:
- To provide an updated overview of emerging and established prostate cancer biomarkers beyond PSA.
- To highlight biomarkers that demonstrate potential for improved diagnostic accuracy and treatment guidance.
Main Methods:
- Review of current research on novel prostate cancer biomarkers.
- Comparison of the performance of new markers against traditional PSA testing (tPSA, fPSA).
- Discussion of biomarkers including PCA 3, proPSA, kallikreins, TMPRSS2:ERG fusion gene, and urokinase plasminogen activation receptor.
Main Results:
- Several biomarkers, including PCA 3 and [-2]proPSA, show improved performance over PSA alone.
- FDA-approved tests exist for PCA 3 and [-2]proPSA; assays for other markers are under development.
- Early PCA research was abandoned due to irreproducible results.
Conclusions:
- Emerging biomarkers offer significant potential to advance prostate cancer diagnosis and treatment.
- Further validation is necessary for widespread clinical acceptance and integration.
- Successful biomarker implementation can enhance patient care and reduce healthcare costs.
